Expand Image

≥99% PurityUS SynthesizedOut of Stock

BPC-157 + TB-500 Research Kit — Separate-Vial Wolverine Stack Components

Research-Grade Compound

The BPC-157 + TB-500 Research Kit supplies the two Wolverine Stack components as separate lyophilized vials rather than a single pre-combined blend. BPC-157 (GEPPPGKPADDAGLV, 1,419.5 Da, CAS 137525-51-0) and TB-500 (synthetic Thymosin β-4, 4,963.4 Da, CAS 77591-33-4), each at ≥99% purity by HPLC with an individual Certificate of Analysis.

Select Size

$70.00$160.00USD / Unit

HPLC Verified

Same Day Shipping

BPC-157 + TB-500 Wolverine Stack research guide →

In-depth research overview, mechanism of action, and study applications.

No reviews yet. Be the first to review this product.

≥99% by HPLCLC-MS/MS VerifiedCoA Every BatchIn-Vitro Research Use Only

What is BPC-157 + TB-500 Kit?

The format matters more than it might appear. A pre-blended vial fixes the ratio between the two compounds at whatever the manufacturer chose. Separate vials let a research protocol vary the ratio, stagger the timing, or run one component as a control arm — which is the only way to attribute an observed effect to a specific mechanism.

If the study design calls for a fixed combination and simplicity, the pre-blended Wolverine Blend is the more practical choice. If the design needs to separate local angiogenesis from systemic cell migration, the kit is the correct format.

How Does BPC-157 + TB-500 Kit Work? Mechanism of Action

Mechanistically the kit is identical to the Wolverine Blend — the same two compounds acting on the same two pathways. BPC-157 upregulates VEGF and activates focal adhesion kinase signaling, driving angiogenesis and fibroblast migration at the local site. TB-500 binds monomeric G-actin through the LKKTET motif, shifting the cytoskeletal equilibrium that determines whether cells throughout the system can migrate toward an injury.

What the separate-vial format changes is experimental control, not pharmacology. Researchers can establish independent dose-response curves for each compound, apply them at different timepoints in a repair cascade, or include single-compound arms in the same experiment — none of which is possible from a fixed blend.

Research Applications of BPC-157 + TB-500 Kit

Mechanism Attribution Studies

Single-compound control arms: the only rigorous way to show that a combination effect exceeds either component alone.
Independent dose-response curves: required before any combination ratio can be justified rather than assumed.
Staggered timing protocols: applying TB-500 to mobilize cells before BPC-157 establishes local vasculature, or the reverse.

Tissue Repair Research

Tendon and ligament models: tensile strength and collagen organization endpoints with mechanism separation.
Gastrointestinal models: BPC-157 carries the mucosal evidence base; TB-500 does not, making a single-compound arm essential here.
Angiogenesis quantification: VEGF and capillary density readouts attributable specifically to the BPC-157 vial.

Separate-Vial Kit vs Pre-Blended Wolverine Blend

Feature	BPC-157 + TB-500 Kit	Wolverine Blend
Format	Two separate lyophilized vials	Single pre-combined vial
Component ratio	Set by the researcher	Fixed at manufacture
Independent dose-response	Possible	Not possible
Single-compound control arm	Possible from the same purchase	Requires buying a separate standalone vial
Staggered timing protocols	Possible	Not possible
Reconstitution steps	Two, one per vial	One
Labelling risk	Real — two clear solutions look identical	None
Certificates of Analysis	Two, one per compound	Two, one per component
Best suited to	Mechanism attribution studies	Fixed-combination protocols

The trade-off is control against convenience, and it is worth being honest about which one a given study actually needs. If the protocol calls for a fixed combination and no single-compound arm, the blend is fewer steps and one less place to make a labelling error. If the protocol needs to say which compound produced an effect, the kit is the only format that can answer that.

BPC-157 + TB-500 Kit Technical Specifications

Technical specifications for BPC-157 + TB-500 Kit, including molecular data, purity standard, testing methods and storage requirements.
Kit Contents	Two separate lyophilized vials — BPC-157 and TB-500
Component 1	BPC-157 — GEPPPGKPADDAGLV, C62H98N16O22, 1,419.5 Da, CAS 137525-51-0
Component 2	TB-500 — synthetic Thymosin β-4, C212H350N56O78S, 4,963.4 Da, CAS 77591-33-4
Purity	≥99% per compound by HPLC
Purity Confirmation	LC-MS/MS molecular weight verification per compound
Endotoxin Testing	LAL (Limulus Amebocyte Lysate) method
Physical Form	Lyophilized powder, separate vials
Reconstitution	Bacteriostatic water, reconstituted independently per vial
Storage (lyophilized)	-20°C, desiccated, protected from light
Storage (reconstituted)	2–8°C, use within 14–28 days
Documentation	Individual Certificate of Analysis per compound
WADA Status	Both compounds prohibited at all times
Intended Use	In-vitro laboratory research only

How to Reconstitute BPC-157 + TB-500 Kit for Research

Reconstitute each vial separately and label both clearly with compound name, concentration and date. Two clear colorless solutions in identical vials are indistinguishable by eye — mislabeling here invalidates the entire reason for choosing the kit format.

Bring both vials to room temperature before opening.
Reconstitute BPC-157 first: for the 10 mg vial, 2 mL of bacteriostatic water yields 5 mg/mL.
Reconstitute TB-500 separately: for the 10 mg vial, 2 mL yields 5 mg/mL. Expect slower dissolution than BPC-157 — TB-500 is roughly 3.5 times the molecular weight.
Inject diluent against the inner vial wall in both cases; swirl 60–90 seconds without shaking.
Verify both solutions are clear and colorless with no particulate.
Label each vial with the compound name, concentration, and reconstitution date. Do not rely on position or memory to tell them apart.
Store both at 2–8°C and use within 14–28 days.

Diluent: bacteriostatic water for peptide reconstitution. Full protocol: step-by-step peptide reconstitution guide. Concentration maths: peptide reconstitution calculator.

Frequently Asked Questions — BPC-157 + TB-500 Kit

What is in the BPC-157 + TB-500 Kit?

Two separate lyophilized vials: BPC-157 (1,419.5 Da, CAS 137525-51-0) and TB-500 (synthetic Thymosin β-4, 4,963.4 Da, CAS 77591-33-4). Each is HPLC-verified at ≥99% purity and ships with its own Certificate of Analysis.

How is the kit different from the Wolverine Blend?

Same two compounds, different format. The Wolverine Blend combines them in one vial at a fixed ratio. The kit keeps them separate, which lets a protocol vary the ratio, stagger timing, or run single-compound control arms.

Why would a research protocol need separate vials?

Because attribution requires it. If a combination produces an effect, you cannot say which compound drove it without single-compound arms in the same experiment. A pre-blended vial makes that impossible. Separate vials also allow independent dose-response characterization before any ratio is chosen.

Can the two vials be combined into one solution?

They can be reconstituted separately and combined afterward, which is what most combination protocols do. Combining them recreates the blend format and gives up the control advantage the kit exists to provide, so it is worth being deliberate about whether the kit was the right purchase.

Do BPC-157 and TB-500 need different reconstitution volumes?

Not inherently — both reconstitute well in bacteriostatic water. What differs is dissolution time. TB-500 at 4,963.4 Da takes noticeably longer to go into solution than BPC-157 at 1,419.5 Da. Judge each by the absence of visible cake rather than by a fixed swirl duration.

What is the Wolverine Stack?

The informal name for a BPC-157 + TB-500 research combination, based on their complementary repair mechanisms: BPC-157 for local VEGF-mediated angiogenesis, TB-500 for systemic actin-mediated cell migration.

Is combination pharmacokinetic data available for these two compounds?

No. No published study characterizes the pharmacokinetics of BPC-157 and TB-500 administered together. The mechanisms are unrelated at the molecular level, which makes interference unlikely, but that is a reasoned expectation rather than a measured result.

Are both compounds in the kit WADA prohibited?

Yes. BPC-157 is prohibited under section S0 and TB-500 under section S2, both at all times, in and out of competition. Neither is FDA-approved for human use.

What purity standard applies to the kit compounds?

≥99% by reverse-phase HPLC for each, with LC-MS/MS confirming 1,419.5 Da for BPC-157 and 4,963.4 Da for TB-500. Two separate Certificates of Analysis ship with the kit.

How should the kit be stored?

Both vials lyophilized at -20°C, desiccated and light-protected, for up to 24 months. Once reconstituted, each at 2–8°C for 14–28 days without freezing.

Where are the Certificates of Analysis for the kit?

On this page and in the Peptide.Express lab results library. Two documents are issued, one per compound, each tied to the specific production batch of the vial in your kit.

Research References

"Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing." Biomolecules, 2025. Read the BPC-157 musculoskeletal healing review on PMC
Goldstein AL, Hannappel E, Kleinman HK. "Thymosin Beta4: Actin-Sequestering Protein Moonlights to Repair Injured Tissues." Trends in Molecular Medicine, 2005. Read the thymosin β4 actin-sequestration and tissue-repair review on PubMed
Sikiric P, Boban Blagaic A, Strbe S, et al. "The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity." Pharmaceuticals, 2024. Read the Sikirić BPC-157 pleiotropic-activity review on PMC

All products are sold for in-vitro laboratory research use only. Not intended for human consumption, clinical use, or veterinary use. Peptide.Express makes no medical claims. Consult the published literature for research application guidance.